What is cutaquig?
Cutaquig is an immunoglobulin replacement therapy for subcutaneous infusion approved for the treatment of primary immunodeficiencies in patients 2 years of age or older
- Cutaquig is made from large pools of donated plasma which go through a rigorous purification process for the inactivation and removal of viruses1
- Cutaquig is manufactured by the cold ethanol fractionation process followed by ultrafiltration and chromatography. The manufacturing process includes treatment with an organic Solvent/Detergent (S/D) mixture composed of tri-n-butyl phosphate (TNBP) and Octoxynol.1
- Viral reduction is achieved through a combination of process steps including cold ethanol fractionation, S/D treatment and pH4 treatment1
- Other precautions against viral transmission include: selection of plasma donors, screening of donations and plasma pool, as well as final product testing for viruses1
Octapharma’s global immunotherapy portfolio offers high-purity human IgG products available in different concentrations and routes of administration in liquid, ready-to-use formulations.
Deliver the complete package of care
Cutaquig provides adult and pediatric patients with primary immunodeficiency the protection, comfort and independence they need to manage their disease:
- Zero SBIs in a Phase 3 Clinical Trial1,8
- Proven Tolerability1,2,8
- Ease of Administration1,2
- Low Viscosity & Easy Injectability2,3
- Favorable Pharmacokinetics1,2,4
- Manufacturing & Pathogen Safety1,4,7
- Flexible Storage & Handling1
- Innovative Patient Support with IgCares
- Cutaquig Full Prescribing Information. Paramus, NJ: Octapharma; rev October 2021.
- Kobayashi RH, Gupta S, Melamed I, et al. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (octanorm [cutaquig®]) in the Treatment of Patients with Primary Immunodeficiencies. Front Immunol. February 2019 | Volume 10 | Article 40.
- Gelbmann N, Zöchling A, Mersich C et al. Cutaquig, Immunoglobulin (human) subcutaneous 16.5% solution for injection (165 mg/mL) – biochemical characterization, pathogen safety and stability. Presented at: 2018 Annual Meeting of the Clinical Immunology Society; Toronto, Canada. Poster Presentation.
- Octapharma, Data on File. 2014.
- McCormack PL. Immune Globulin Subcutaneous (Human) 20% In Primary Immunodeficiency Disorders. Drugs. 2012; 72 (8): 1087-1097.
- Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics: Targets and Therapy.2012:6 277–287.
- Buchacher A, Kaar W. Intravenous immunoglobulin G from human plasma–purification concepts and important quality criteria. In: Bertolini J, Goss N, Curling J, eds. Production of Plasma Proteins for Therapeutic Use. Hoboken, NJ: John Wiley & Sons, Inc; 2013.
- Kobayashi RH, Mandujano JF, Rehman SM, et al. Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig® [octanorm]). Immunotherapy. 2021;13(10):813 -824.